OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call...
Year: 2024
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain...
Celularity Inc. to Host Investor and Analyst Research & Development Day
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial ProgressFLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE)...
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024
Treatment with EBT-104 resulted in over 90% reduction in viral shedding in HSV-1 Keratitis modelSAN FRANCISCO, April 22, 2024 (GLOBE...
SS Innovations International Announces Q1 2024 Company Updates
Significant milestones achieved for SSi Mantra Made-in-India surgical robotic system FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS...
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial's lower-than-expected event rate suggests improved survival outcomesMINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”),...
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused...
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and...
Stereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for...
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial...
Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
ANN ARBOR, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"),...
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase...
XORTX Announces Publication of Key Research in ADPKD
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving...